International Flavors & Fragrances Inc
Change company Symbol lookup
Select an option...
IFF International Flavors & Fragrances Inc
NEMD iNeedMD Holdings Inc
CVS CVS Health Corp
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
Go

Materials : Chemicals | Mid Cap Blend
Company profile

International Flavors & Fragrances Inc. provides products that consumers taste, smell, or touch. It operates through three segments: Taste, Frutarom and Scent. Taste is comprised of Flavor Compounds which are sold to the food and beverage industries for use in consumer products, such as prepared foods, beverages, dairy, food and sweet products. Frutarom segment creates and manufactures a naturals-focused suite of flavor compounds, functional foods and specialty fine ingredients. Scent segment is comprised of Fragrance Compounds, which are used by its customers in two broad categories: Fine Fragrances and Consumer Fragrances; Fragrance Ingredients, which consists of synthetic and natural ingredients that can be combined with other materials to create fragrance and consumer compounds; and Cosmetic Active Ingredients, consisting of active and functional ingredients, botanicals and delivery systems.

Closing Price
$102.66
Day's Change
-0.26 (-0.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
103.35
Day's Low
101.41
Volume
(Average)
Volume:
1,564,092

10-day average volume:
1,554,239
1,564,092

Gilead coronavirus drug use expanded to include moderate cases

5:10 pm ET August 28, 2020 (MarketWatch)
Print

Wallace Witkowski

Gilead Sciences Inc. (GILD) said late Friday it received emergency U.S. approval for treatment for COVID-19 patients with a moderate form of the disease.

Gilead said the Food and Drug Administration expanded it emergency use of the antiviral drug Veklury, also known as remdesivir, to treat moderate cases of COVID-19 in hospitals, instead of just severe cases.

The expansion is based on data from a late-stage clinical trial (https://www.marketwatch.com/story/gileads-remdesivir-may-benefit-moderately-ill-covid-19-patients-but-findings-uncertain-2020-08-25) that showed that COVID-19 patients given Veklury along with standard treatment were 65% more likely to show an improvement than patients given standard treatment alone, Gilead said.

Shares of Gilead were up 0.8% after hours, following a 0.4% decline in the regular session to close at $65.26. Gilead shares are up 0.4% for the year, compared with an 8.6% gain in the S&P 500 index .

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 28, 2020 17:10 ET (21:10 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.